Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998;77(3):448–455. doi: 10.1038/bjc.1998.71

The ubiquitin-proteasome pathway in cancer.

V Spataro 1, C Norbury 1, A L Harris 1
PMCID: PMC2151296  PMID: 9472642

Abstract

Degradation by the 26S proteasome of specific proteins that have been targeted by the ubiquitin pathway is the major intracellular non-lysosomal proteolytic mechanism and is involved in a broad range of processes, such as cell cycle progression, antigen presentation and control of gene expression. Recent work, reviewed here, has shown that this pathway is often the target of cancer-related deregulation and can underlie processes, such as oncogenic transformation, tumour progression, escape from immune surveillance and drug resistance.

Full text

PDF
448

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amon A., Irniger S., Nasmyth K. Closing the cell cycle circle in yeast: G2 cyclin proteolysis initiated at mitosis persists until the activation of G1 cyclins in the next cycle. Cell. 1994 Jul 1;77(7):1037–1050. doi: 10.1016/0092-8674(94)90443-x. [DOI] [PubMed] [Google Scholar]
  2. Beck S., Kelly A., Radley E., Khurshid F., Alderton R. P., Trowsdale J. DNA sequence analysis of 66 kb of the human MHC class II region encoding a cluster of genes for antigen processing. J Mol Biol. 1992 Nov 20;228(2):433–441. doi: 10.1016/0022-2836(92)90832-5. [DOI] [PubMed] [Google Scholar]
  3. Beg A. A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996 Nov 1;274(5288):782–784. doi: 10.1126/science.274.5288.782. [DOI] [PubMed] [Google Scholar]
  4. Belich M. P., Glynne R. J., Senger G., Sheer D., Trowsdale J. Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins. Curr Biol. 1994 Sep 1;4(9):769–776. doi: 10.1016/s0960-9822(00)00174-3. [DOI] [PubMed] [Google Scholar]
  5. Betticher D. C. Cyclin D1, another molecule of the year? Ann Oncol. 1996 Mar;7(3):223–225. doi: 10.1093/oxfordjournals.annonc.a010563. [DOI] [PubMed] [Google Scholar]
  6. Brandeis M., Hunt T. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBO J. 1996 Oct 1;15(19):5280–5289. [PMC free article] [PubMed] [Google Scholar]
  7. Catzavelos C., Bhattacharya N., Ung Y. C., Wilson J. A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997 Feb;3(2):227–230. doi: 10.1038/nm0297-227. [DOI] [PubMed] [Google Scholar]
  8. Cerundolo V., Benham A., Braud V., Mukherjee S., Gould K., Macino B., Neefjes J., Townsend A. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol. 1997 Jan;27(1):336–341. doi: 10.1002/eji.1830270148. [DOI] [PubMed] [Google Scholar]
  9. Chowdary D. R., Dermody J. J., Jha K. K., Ozer H. L. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol. 1994 Mar;14(3):1997–2003. doi: 10.1128/mcb.14.3.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ciechanover A., Shkedy D., Oren M., Bercovich B. Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2. J Biol Chem. 1994 Apr 1;269(13):9582–9589. [PubMed] [Google Scholar]
  11. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994 Oct 7;79(1):13–21. doi: 10.1016/0092-8674(94)90396-4. [DOI] [PubMed] [Google Scholar]
  12. Ciocca D. R., Fuqua S. A., Lock-Lim S., Toft D. O., Welch W. J., McGuire W. L. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 1992 Jul 1;52(13):3648–3654. [PubMed] [Google Scholar]
  13. Claret F. X., Hibi M., Dhut S., Toda T., Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature. 1996 Oct 3;383(6599):453–457. doi: 10.1038/383453a0. [DOI] [PubMed] [Google Scholar]
  14. Clurman B. E., Sheaff R. J., Thress K., Groudine M., Roberts J. M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996 Aug 15;10(16):1979–1990. doi: 10.1101/gad.10.16.1979. [DOI] [PubMed] [Google Scholar]
  15. Cox L. S., Lane D. P. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays. 1995 Jun;17(6):501–508. doi: 10.1002/bies.950170606. [DOI] [PubMed] [Google Scholar]
  16. Diehl J. A., Zindy F., Sherr C. J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997 Apr 15;11(8):957–972. doi: 10.1101/gad.11.8.957. [DOI] [PubMed] [Google Scholar]
  17. Dubiel W., Ferrell K., Dumdey R., Standera S., Prehn S., Rechsteiner M. Molecular cloning and expression of subunit 12: a non-MCP and non-ATPase subunit of the 26 S protease. FEBS Lett. 1995 Apr 17;363(1-2):97–100. doi: 10.1016/0014-5793(95)00288-k. [DOI] [PubMed] [Google Scholar]
  18. Dubiel W., Ferrell K., Rechsteiner M. Subunits of the regulatory complex of the 26S protease. Mol Biol Rep. 1995;21(1):27–34. doi: 10.1007/BF00990967. [DOI] [PubMed] [Google Scholar]
  19. Fehling H. J., Swat W., Laplace C., Kühn R., Rajewsky K., Müller U., von Boehmer H. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science. 1994 Aug 26;265(5176):1234–1237. doi: 10.1126/science.8066463. [DOI] [PubMed] [Google Scholar]
  20. Fenteany G., Standaert R. F., Lane W. S., Choi S., Corey E. J., Schreiber S. L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 1995 May 5;268(5211):726–731. doi: 10.1126/science.7732382. [DOI] [PubMed] [Google Scholar]
  21. Fenteany G., Standaert R. F., Reichard G. A., Corey E. J., Schreiber S. L. A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3358–3362. doi: 10.1073/pnas.91.8.3358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ferrando A. A., Balbín M., Pendás A. M., Vizoso F., Velasco G., López-Otín C. Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. Hum Genet. 1996 Jan;97(1):91–94. doi: 10.1007/BF00218840. [DOI] [PubMed] [Google Scholar]
  23. Figueiredo-Pereira M. E., Chen W. E., Li J., Johdo O. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J Biol Chem. 1996 Jul 12;271(28):16455–16459. doi: 10.1074/jbc.271.28.16455. [DOI] [PubMed] [Google Scholar]
  24. Fornerod M., van Deursen J., van Baal S., Reynolds A., Davis D., Murti K. G., Fransen J., Grosveld G. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J. 1997 Feb 17;16(4):807–816. doi: 10.1093/emboj/16.4.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Früh K., Gossen M., Wang K., Bujard H., Peterson P. A., Yang Y. Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J. 1994 Jul 15;13(14):3236–3244. doi: 10.1002/j.1460-2075.1994.tb06625.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Fujita E., Mukasa T., Tsukahara T., Arahata K., Omura S., Momoi T. Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors. Biochem Biophys Res Commun. 1996 Jul 5;224(1):74–79. doi: 10.1006/bbrc.1996.0986. [DOI] [PubMed] [Google Scholar]
  27. Gaczynska M., Goldberg A. L., Tanaka K., Hendil K. B., Rock K. L. Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7. J Biol Chem. 1996 Jul 19;271(29):17275–17280. doi: 10.1074/jbc.271.29.17275. [DOI] [PubMed] [Google Scholar]
  28. Glotzer M., Murray A. W., Kirschner M. W. Cyclin is degraded by the ubiquitin pathway. Nature. 1991 Jan 10;349(6305):132–138. doi: 10.1038/349132a0. [DOI] [PubMed] [Google Scholar]
  29. Gordon C., McGurk G., Dillon P., Rosen C., Hastie N. D. Defective mitosis due to a mutation in the gene for a fission yeast 26S protease subunit. Nature. 1993 Nov 25;366(6453):355–357. doi: 10.1038/366355a0. [DOI] [PubMed] [Google Scholar]
  30. Gordon C., McGurk G., Wallace M., Hastie N. D. A conditional lethal mutant in the fission yeast 26 S protease subunit mts3+ is defective in metaphase to anaphase transition. J Biol Chem. 1996 Mar 8;271(10):5704–5711. doi: 10.1074/jbc.271.10.5704. [DOI] [PubMed] [Google Scholar]
  31. Gray D. A., Inazawa J., Gupta K., Wong A., Ueda R., Takahashi T. Elevated expression of Unph, a proto-oncogene at 3p21.3, in human lung tumors. Oncogene. 1995 Jun 1;10(11):2179–2183. [PubMed] [Google Scholar]
  32. Groettrup M., Kraft R., Kostka S., Standera S., Stohwasser R., Kloetzel P. M. A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur J Immunol. 1996 Apr;26(4):863–869. doi: 10.1002/eji.1830260421. [DOI] [PubMed] [Google Scholar]
  33. Groettrup M., Ruppert T., Kuehn L., Seeger M., Standera S., Koszinowski U., Kloetzel P. M. The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J Biol Chem. 1995 Oct 6;270(40):23808–23815. doi: 10.1074/jbc.270.40.23808. [DOI] [PubMed] [Google Scholar]
  34. Groll M., Ditzel L., Löwe J., Stock D., Bochtler M., Bartunik H. D., Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature. 1997 Apr 3;386(6624):463–471. doi: 10.1038/386463a0. [DOI] [PubMed] [Google Scholar]
  35. Harris C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996 Oct 16;88(20):1442–1455. doi: 10.1093/jnci/88.20.1442. [DOI] [PubMed] [Google Scholar]
  36. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997 May 15;387(6630):296–299. doi: 10.1038/387296a0. [DOI] [PubMed] [Google Scholar]
  37. Hengst L., Reed S. I. Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996 Mar 29;271(5257):1861–1864. doi: 10.1126/science.271.5257.1861. [DOI] [PubMed] [Google Scholar]
  38. Hermida-Matsumoto M. L., Chock P. B., Curran T., Yang D. C. Ubiquitinylation of transcription factors c-Jun and c-Fos using reconstituted ubiquitinylating enzymes. J Biol Chem. 1996 Mar 1;271(9):4930–4936. doi: 10.1074/jbc.271.9.4930. [DOI] [PubMed] [Google Scholar]
  39. Hisamatsu H., Shimbara N., Saito Y., Kristensen P., Hendil K. B., Fujiwara T., Takahashi E., Tanahashi N., Tamura T., Ichihara A. Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma. J Exp Med. 1996 Apr 1;183(4):1807–1816. doi: 10.1084/jem.183.4.1807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol. 1995 Apr;7(2):215–223. doi: 10.1016/0955-0674(95)80031-x. [DOI] [PubMed] [Google Scholar]
  41. Hou D., Cenciarelli C., Jensen J. P., Nguygen H. B., Weissman A. M. Activation-dependent ubiquitination of a T cell antigen receptor subunit on multiple intracellular lysines. J Biol Chem. 1994 May 13;269(19):14244–14247. [PubMed] [Google Scholar]
  42. Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994 Nov 18;79(4):573–582. doi: 10.1016/0092-8674(94)90543-6. [DOI] [PubMed] [Google Scholar]
  43. Ikehata H., Kaneda S., Yamao F., Seno T., Ono T., Hanaoka F. Incubation at the nonpermissive temperature induces deficiencies in UV resistance and mutagenesis in mouse mutant cells expressing a temperature-sensitive ubiquitin-activating enzyme (E1). Mol Cell Biol. 1997 Mar;17(3):1484–1489. doi: 10.1128/mcb.17.3.1484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Imajoh-Ohmi S., Kawaguchi T., Sugiyama S., Tanaka K., Omura S., Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun. 1995 Dec 26;217(3):1070–1077. doi: 10.1006/bbrc.1995.2878. [DOI] [PubMed] [Google Scholar]
  45. Jariel-Encontre I., Pariat M., Martin F., Carillo S., Salvat C., Piechaczyk M. Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26 S proteasome. J Biol Chem. 1995 May 12;270(19):11623–11627. doi: 10.1074/jbc.270.19.11623. [DOI] [PubMed] [Google Scholar]
  46. Keyomarsi K., Conte D., Jr, Toyofuku W., Fox M. P. Deregulation of cyclin E in breast cancer. Oncogene. 1995 Sep 7;11(5):941–950. [PubMed] [Google Scholar]
  47. Keyomarsi K., O'Leary N., Molnar G., Lees E., Fingert H. J., Pardee A. B. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res. 1994 Jan 15;54(2):380–385. [PubMed] [Google Scholar]
  48. Keyomarsi K., Pardee A. B. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1112–1116. doi: 10.1073/pnas.90.3.1112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. King R. W., Deshaies R. J., Peters J. M., Kirschner M. W. How proteolysis drives the cell cycle. Science. 1996 Dec 6;274(5293):1652–1659. doi: 10.1126/science.274.5293.1652. [DOI] [PubMed] [Google Scholar]
  50. Kuckelkorn U., Frentzel S., Kraft R., Kostka S., Groettrup M., Kloetzel P. M. Incorporation of major histocompatibility complex--encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur J Immunol. 1995 Sep;25(9):2605–2611. doi: 10.1002/eji.1830250930. [DOI] [PubMed] [Google Scholar]
  51. Kumada K., Yanagida M., Toda T. Caffeine-resistance in fission yeast is caused by mutations in a single essential gene, crm1+. Mol Gen Genet. 1996 Jan 15;250(1):59–68. doi: 10.1007/BF02191825. [DOI] [PubMed] [Google Scholar]
  52. Lam Y. A., Xu W., DeMartino G. N., Cohen R. E. Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature. 1997 Feb 20;385(6618):737–740. doi: 10.1038/385737a0. [DOI] [PubMed] [Google Scholar]
  53. Lee H. W., Smith L., Pettit G. R., Vinitsky A., Smith J. B. Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J Biol Chem. 1996 Aug 30;271(35):20973–20976. [PubMed] [Google Scholar]
  54. Lillington D. M., MacCallum P. K., Lister T. A., Gibbons B. Translocation t(6;9)(p23;q34) in acute myeloid leukemia without myelodysplasia or basophilia: two cases and a review of the literature. Leukemia. 1993 Apr;7(4):527–531. [PubMed] [Google Scholar]
  55. Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. F., Jessup J. M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997 Feb;3(2):231–234. doi: 10.1038/nm0297-231. [DOI] [PubMed] [Google Scholar]
  56. Löwe J., Stock D., Jap B., Zwickl P., Baumeister W., Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science. 1995 Apr 28;268(5210):533–539. doi: 10.1126/science.7725097. [DOI] [PubMed] [Google Scholar]
  57. Maki C. G., Huibregtse J. M., Howley P. M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996 Jun 1;56(11):2649–2654. [PubMed] [Google Scholar]
  58. Masutani C., Sugasawa K., Yanagisawa J., Sonoyama T., Ui M., Enomoto T., Takio K., Tanaka K., van der Spek P. J., Bootsma D. Purification and cloning of a nucleotide excision repair complex involving the xeroderma pigmentosum group C protein and a human homologue of yeast RAD23. EMBO J. 1994 Apr 15;13(8):1831–1843. doi: 10.1002/j.1460-2075.1994.tb06452.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Michalek M. T., Grant E. P., Gramm C., Goldberg A. L., Rock K. L. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature. 1993 Jun 10;363(6429):552–554. doi: 10.1038/363552a0. [DOI] [PubMed] [Google Scholar]
  60. Moffat G. J., McLaren A. W., Wolf C. R. Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells. J Biol Chem. 1994 Jun 10;269(23):16397–16402. [PubMed] [Google Scholar]
  61. Mori S., Kanaki H., Tanaka K., Morisaki N., Saito Y. Ligand-activated platelet-derived growth factor beta-receptor is degraded through proteasome-dependent proteolytic pathway. Biochem Biophys Res Commun. 1995 Dec 5;217(1):224–229. doi: 10.1006/bbrc.1995.2767. [DOI] [PubMed] [Google Scholar]
  62. Morosétti R., Kawamata N., Gombart A. F., Miller C. W., Hatta Y., Hirama T., Said J. W., Tomonaga M., Koeffler H. P. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood. 1995 Sep 1;86(5):1924–1930. [PubMed] [Google Scholar]
  63. Musti A. M., Treier M., Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science. 1997 Jan 17;275(5298):400–402. doi: 10.1126/science.275.5298.400. [DOI] [PubMed] [Google Scholar]
  64. Nandi D., Jiang H., Monaco J. J. Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol. 1996 Apr 1;156(7):2361–2364. [PubMed] [Google Scholar]
  65. Pagano M., Tam S. W., Theodoras A. M., Beer-Romero P., Del Sal G., Chau V., Yew P. R., Draetta G. F., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995 Aug 4;269(5224):682–685. doi: 10.1126/science.7624798. [DOI] [PubMed] [Google Scholar]
  66. Pahl H. L., Baeuerle P. A. Control of gene expression by proteolysis. Curr Opin Cell Biol. 1996 Jun;8(3):340–347. doi: 10.1016/s0955-0674(96)80007-x. [DOI] [PubMed] [Google Scholar]
  67. Palombella V. J., Rando O. J., Goldberg A. L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994 Sep 9;78(5):773–785. doi: 10.1016/s0092-8674(94)90482-0. [DOI] [PubMed] [Google Scholar]
  68. Papa F. R., Hochstrasser M. The yeast DOA4 gene encodes a deubiquitinating enzyme related to a product of the human tre-2 oncogene. Nature. 1993 Nov 25;366(6453):313–319. doi: 10.1038/366313a0. [DOI] [PubMed] [Google Scholar]
  69. Peters J. M., Cejka Z., Harris J. R., Kleinschmidt J. A., Baumeister W. Structural features of the 26 S proteasome complex. J Mol Biol. 1993 Dec 20;234(4):932–937. doi: 10.1006/jmbi.1993.1646. [DOI] [PubMed] [Google Scholar]
  70. Peters J. M. Proteasomes: protein degradation machines of the cell. Trends Biochem Sci. 1994 Sep;19(9):377–382. doi: 10.1016/0968-0004(94)90115-5. [DOI] [PubMed] [Google Scholar]
  71. Philip P. A., Harris A. L. Potential for protein kinase C inhibitors in cancer therapy. Cancer Treat Res. 1995;78:3–27. doi: 10.1007/978-1-4615-2007-8_1. [DOI] [PubMed] [Google Scholar]
  72. Pinkus R., Weiner L. M., Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem. 1996 Jun 7;271(23):13422–13429. doi: 10.1074/jbc.271.23.13422. [DOI] [PubMed] [Google Scholar]
  73. Polyak K., Kato J. Y., Solomon M. J., Sherr C. J., Massague J., Roberts J. M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994 Jan;8(1):9–22. doi: 10.1101/gad.8.1.9. [DOI] [PubMed] [Google Scholar]
  74. Porter P. L., Malone K. E., Heagerty P. J., Alexander G. M., Gatti L. A., Firpo E. J., Daling J. R., Roberts J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997 Feb;3(2):222–225. doi: 10.1038/nm0297-222. [DOI] [PubMed] [Google Scholar]
  75. Restifo N. P., Esquivel F., Kawakami Y., Yewdell J. W., Mulé J. J., Rosenberg S. A., Bennink J. R. Identification of human cancers deficient in antigen processing. J Exp Med. 1993 Feb 1;177(2):265–272. doi: 10.1084/jem.177.2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Ritke M. K., Bergoltz V. V., Allan W. P., Yalowich J. C. Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem Pharmacol. 1994 Aug 3;48(3):525–533. doi: 10.1016/0006-2952(94)90282-8. [DOI] [PubMed] [Google Scholar]
  77. Rock K. L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., Goldberg A. L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994 Sep 9;78(5):761–771. doi: 10.1016/s0092-8674(94)90462-6. [DOI] [PubMed] [Google Scholar]
  78. Rolfe M., Beer-Romero P., Glass S., Eckstein J., Berdo I., Theodoras A., Pagano M., Draetta G. Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3264–3268. doi: 10.1073/pnas.92.8.3264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Rotem-Yehudar R., Groettrup M., Soza A., Kloetzel P. M., Ehrlich R. LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med. 1996 Feb 1;183(2):499–514. doi: 10.1084/jem.183.2.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Rubin D. M., Finley D. Proteolysis. The proteasome: a protein-degrading organelle? Curr Biol. 1995 Aug 1;5(8):854–858. doi: 10.1016/s0960-9822(95)00172-2. [DOI] [PubMed] [Google Scholar]
  81. Sadoul R., Fernandez P. A., Quiquerez A. L., Martinou I., Maki M., Schröter M., Becherer J. D., Irmler M., Tschopp J., Martinou J. C. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J. 1996 Aug 1;15(15):3845–3852. [PMC free article] [PubMed] [Google Scholar]
  82. Scheffner M., Huibregtse J. M., Vierstra R. D., Howley P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993 Nov 5;75(3):495–505. doi: 10.1016/0092-8674(93)90384-3. [DOI] [PubMed] [Google Scholar]
  83. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990 Dec 21;63(6):1129–1136. doi: 10.1016/0092-8674(90)90409-8. [DOI] [PubMed] [Google Scholar]
  84. Schreiber M., Baumann B., Cotten M., Angel P., Wagner E. F. Fos is an essential component of the mammalian UV response. EMBO J. 1995 Nov 1;14(21):5338–5349. doi: 10.1002/j.1460-2075.1995.tb00218.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Seliger B., Hohne A., Knuth A., Bernhard H., Meyer T., Tampe R., Momburg F., Huber C. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. 1996 Apr 15;56(8):1756–1760. [PubMed] [Google Scholar]
  86. Sepp-Lorenzino L., Ma Z., Lebwohl D. E., Vinitsky A., Rosen N. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem. 1995 Jul 14;270(28):16580–16587. doi: 10.1074/jbc.270.28.16580. [DOI] [PubMed] [Google Scholar]
  87. Shaeffer J. R., Cohen R. E. Differential effects of ubiquitin aldehyde on ubiquitin and ATP-dependent protein degradation. Biochemistry. 1996 Aug 20;35(33):10886–10893. doi: 10.1021/bi9530705. [DOI] [PubMed] [Google Scholar]
  88. Shimanuki M., Saka Y., Yanagida M., Toda T. A novel essential fission yeast gene pad1+ positively regulates pap1(+)-dependent transcription and is implicated in the maintenance of chromosome structure. J Cell Sci. 1995 Feb;108(Pt 2):569–579. doi: 10.1242/jcs.108.2.569. [DOI] [PubMed] [Google Scholar]
  89. Shinohara K., Tomioka M., Nakano H., Toné S., Ito H., Kawashima S. Apoptosis induction resulting from proteasome inhibition. Biochem J. 1996 Jul 15;317(Pt 2):385–388. doi: 10.1042/bj3170385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Sibille C., Gould K. G., Willard-Gallo K., Thomson S., Rivett A. J., Powis S., Butcher G. W., De Baetselier P. LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes. Curr Biol. 1995 Aug 1;5(8):923–930. doi: 10.1016/s0960-9822(95)00182-5. [DOI] [PubMed] [Google Scholar]
  91. Slingerland J. M., Hengst L., Pan C. H., Alexander D., Stampfer M. R., Reed S. I. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol. 1994 Jun;14(6):3683–3694. doi: 10.1128/mcb.14.6.3683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Toda T., Shimanuki M., Saka Y., Yamano H., Adachi Y., Shirakawa M., Kyogoku Y., Yanagida M. Fission yeast pap1-dependent transcription is negatively regulated by an essential nuclear protein, crm1. Mol Cell Biol. 1992 Dec;12(12):5474–5484. doi: 10.1128/mcb.12.12.5474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Treier M., Staszewski L. M., Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell. 1994 Sep 9;78(5):787–798. doi: 10.1016/s0092-8674(94)90502-9. [DOI] [PubMed] [Google Scholar]
  94. Tsurumi C., DeMartino G. N., Slaughter C. A., Shimbara N., Tanaka K. cDNA cloning of p40, a regulatory subunit of the human 26S proteasome, and a homolog of the Mov-34 gene product. Biochem Biophys Res Commun. 1995 May 16;210(2):600–608. doi: 10.1006/bbrc.1995.1701. [DOI] [PubMed] [Google Scholar]
  95. Tsurumi C., Ishida N., Tamura T., Kakizuka A., Nishida E., Okumura E., Kishimoto T., Inagaki M., Okazaki K., Sagata N. Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Mol Cell Biol. 1995 Oct;15(10):5682–5687. doi: 10.1128/mcb.15.10.5682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Van Antwerp D. J., Martin S. J., Kafri T., Green D. R., Verma I. M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996 Nov 1;274(5288):787–789. doi: 10.1126/science.274.5288.787. [DOI] [PubMed] [Google Scholar]
  97. Wang C. Y., Mayo M. W., Baldwin A. S., Jr TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996 Nov 1;274(5288):784–787. doi: 10.1126/science.274.5288.784. [DOI] [PubMed] [Google Scholar]
  98. Watkins J. F., Sung P., Prakash L., Prakash S. The Saccharomyces cerevisiae DNA repair gene RAD23 encodes a nuclear protein containing a ubiquitin-like domain required for biological function. Mol Cell Biol. 1993 Dec;13(12):7757–7765. doi: 10.1128/mcb.13.12.7757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Yao K. S., Godwin A. K., Johnson S. W., Ozols R. F., O'Dwyer P. J., Hamilton T. C. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res. 1995 Oct 1;55(19):4367–4374. [PubMed] [Google Scholar]
  100. Zhou M., Wu X., Ginsberg H. N. Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells. J Biol Chem. 1996 Oct 4;271(40):24769–24775. doi: 10.1074/jbc.271.40.24769. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES